Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report ; volume:12 ; number:3 ; year:2019 ; pages:922-927
Case reports in oncology ; 12, Heft 3 (2019), 922-927
- Creator
-
Mohamed, Shehab F.
Helmi, Feryal
El-Akiki, Susanna
El Omri, Halima
Nashwan, Abdulqadir
Yassin, Mohamed A.
- DOI
-
10.1159/000504929
- URN
-
urn:nbn:de:101:1-2020011600202096588609
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mohamed, Shehab F.
- Helmi, Feryal
- El-Akiki, Susanna
- El Omri, Halima
- Nashwan, Abdulqadir
- Yassin, Mohamed A.
Other Objects (12)
Concomitant uveal melanoma and papillary thyroid carcinoma: a case report
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study
Concomitant uveal melanoma and papillary thyroid carcinoma: a case report
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study
Concomitant uveal melanoma and papillary thyroid carcinoma: a case report
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma